## **CLAIMS**

1. An isolated nucleic acid encoding an *M. catarrhalis* polypeptide of SEQ ID NOS: 1921-3840.

5

- 2. A recombinant expression vector comprising the nucleic acid of Claim 1 operably linked to a transcription regulatory element.
- 3. A cell comprising a recombinant expression vector of Claim 2.

10

- 4. A method for producing an *M. catarrhalis* polypeptide comprising culturing a cell of Claim 3 under conditions that permit expression of the polypeptide.
- 5. An isolated nucleic acid selected from the group consisting of:

15

- (a) SEQ ID NOS: 1-1920;
- (b) a complement of SEQ ID NOS: 1-1920; or
- (c) an RNA of (a) or (b), wherein U is substituted for T.
- 6. A recombinant expression vector comprising the nucleic acid of Claim 5 operably linked to a transcription regulatory element.
  - 7. A cell comprising a recombinant expression vector of Claim 6.
- 8. A method for producing an *M. catarrhalis* polypeptide comprising culturing a cell of Claim 7 under conditions that permit expression of the polypeptide.

## Application Docket No.: PATH03-14

- 9. A probe comprising a nucleotide sequence consisting of at least eight contiguous nucleotides of a nucleotide sequence selected from the group consisting of:
  - (a) SEQ ID NOS: 1-1920;
  - (b) a complement of SEQ ID NOS: 1-1920; or
- 5 (c) an RNA of (a) or (b), wherein U is substituted for T.
  - 10. An isolated nucleic acid comprising a nucleotide sequence of at least eight nucleotides in length, wherein the sequence is hybridizable to a nucleic acid having a nucleotide sequence selected from the group consisting of:
- 10 (a) SEQ ID NOS: 1-1920;
  - (b) a complement of SEQ ID NOS: 1-1920; or
  - (c) an RNA of (a) or (b), wherein U is substituted for T..
- 11. A vaccine composition for prevention or treatment of an *M. catarrhalis* infection comprising a nucleic acid of Claim 5 and a pharmaceutically acceptable carrier.
  - 12. A vaccine composition of Claim 11, further comprising an adjuvant.
- 13. A vaccine composition of Claim 11, further comprising one or more additional ingredients.
  - 14. A method of treating a subject for *M. catarrhalis* infection comprising administering to a subject a vaccine composition of Claim 11, such that treatment of *M. catarrhalis* infection occurs.

25

- 15. A method of Claim 14, wherein the treatment is a prophylactic treatment.
- 16. A method of Claim 14, wherein the treatment is a therapeutic treatment.

## Application Docket No.: PATH03-14

10

25

.30

- 17. A recombinant or substantially pure preparation of an *M. catarrhalis* polypeptide or a fragment thereof, wherein said *M. catarrhalis* polypeptide is SEQ ID NOS: 1921-3840.
- A vaccine composition for prevention or treatment of an *M. catarrhalis* infection comprising an *M. catarrhalis* polypeptide of Claim 17 and a pharmaceutically acceptable carrier.
  - 19. A vaccine composition of Claim 18, further comprising an adjuvant.

20. A vaccine composition of Claim 18, further comprising one or more additional ingredients.

- A method of treating a subject for *M. catarrhalis* infection comprising administering to a subject a vaccine composition of Claim 18, such that treatment of *M. catarrhalis* infection occurs.
  - 22. A method of Claim 21, wherein the treatment is a prophylactic treatment.
- 20 23. A method of Claim 21, wherein the treatment is a therapeutic treatment.
  - 24. A method for detecting the presence or absence of a *Klebsiella* nucleic acid in a sample comprising:
  - (a) contacting a sample with the nucleic acid of Claim 5 under conditions in which a hybrid can form between a probe comprising a nucleotide sequence consisting of at least eight contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-2501 or a complement of SEQ ID NOS: 1-1920 and a Klebsiella nucleic acid in the sample; and
    - (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence or absence of a *Klebsiella* nucleic acid in the sample.

15

- 25., A computer readable medium having recorded thereon a nucleotide sequence selected from the group consisting of:
  - (a) SEQ ID NOS: 1-1920;
- 5 (b) a complement of SEQ ID NOS: 1- 1920;
  - (c) an RNA of (a) or (b), wherein U is substituted for T; or
  - (d) a fragment of (a), (b) or (c).
- A computer based system for identifying fragments of the *Klebsiella* genome of comprising;
  - a data storage means comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-1920, a complement of SEQ ID NOS: 1-1920, or a fragment thereof,
  - b) a search means for comparing a target sequence to the nucleotide sequences of the data storage means of step (a) to identify homologous sequences, and;
  - c) a retrieval means for obtaining said homologous sequences(s) of step (b).
- A method of identifying nucleic acid fragments of a Klebsiella genome comprising comparing a database comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-1920; a complement of SEQ ID NOS: 1-1920; or a fragment thereof with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to said target sequence, wherein said target sequence is not randomly selected.
- 25 28. A method for identifying an expression modulating fragment of the *Klebsiella* genome comprising comparing a database comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-1920; a complement of SEQ ID NOS: 1-1920; or fragment thereof with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to said target sequence, wherein said target sequence comprises sequences known to regulate gene expression.